310 related articles for article (PubMed ID: 21169390)
1. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
Hasnain M; Fredrickson SK; Vieweg WV
J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
[TBL] [Abstract][Full Text] [Related]
2. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
Miller LJ
Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
Ellinger LK; Ipema HJ; Stachnik JM
Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
[TBL] [Abstract][Full Text] [Related]
4. The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
Khan AY; Macaluso M; McHale RJ; Dahmen MM; Girrens K; Ali F
J Psychiatr Pract; 2010 Sep; 16(5):289-96. PubMed ID: 20859106
[TBL] [Abstract][Full Text] [Related]
5. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Baptista T; Kin NM; Beaulieu S; de Baptista EA
Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
[TBL] [Abstract][Full Text] [Related]
6. Metabolic risk during antipsychotic treatment.
Newcomer JW
Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
[TBL] [Abstract][Full Text] [Related]
7. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.
Hasnain M; Vieweg WV; Hollett B
Postgrad Med; 2012 Jul; 124(4):154-67. PubMed ID: 22913904
[TBL] [Abstract][Full Text] [Related]
8. Schizophrenia, obesity, and antipsychotic medications: what can we do?
Citrome L; Vreeland B
Postgrad Med; 2008 Jul; 120(2):18-33. PubMed ID: 18654065
[TBL] [Abstract][Full Text] [Related]
9. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
Rzewuska M
Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
[TBL] [Abstract][Full Text] [Related]
10. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
Monteleone P; Martiadis V; Maj M
Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
Rege S
Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
[TBL] [Abstract][Full Text] [Related]
12. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl SM; Mignon L; Meyer JM
Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review.
Newall H; Myles N; Ward PB; Samaras K; Shiers D; Curtis J
Int Clin Psychopharmacol; 2012 Mar; 27(2):69-75. PubMed ID: 21979790
[TBL] [Abstract][Full Text] [Related]
14. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.
Van Gaal LF
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S142-8. PubMed ID: 16863690
[TBL] [Abstract][Full Text] [Related]
15. Schizophrenia and obesity: impact of antipsychotic medications.
Wirshing DA
J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
[TBL] [Abstract][Full Text] [Related]
16. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
17. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
18. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Wu RR; Zhao JP; Jin H; Shao P; Fang MS; Guo XF; He YQ; Liu YJ; Chen JD; Li LH
JAMA; 2008 Jan; 299(2):185-93. PubMed ID: 18182600
[TBL] [Abstract][Full Text] [Related]
19. [Atypical antipsychotic induced weight gain and metabolic disorders].
Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C
Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331
[TBL] [Abstract][Full Text] [Related]
20. Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?
Housel AK; Waterbury N; Argo TR
Issues Ment Health Nurs; 2009 Dec; 30(12):803-5. PubMed ID: 19916816
[No Abstract] [Full Text] [Related]
[Next] [New Search]
